Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial

Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial

Abstract Objective The present study is a phase I/IIa non-randomized, open-label study to evaluate safety and efficacy of a single, intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs) over a period of 52 weeks, in patients with active rheumatoid arthritis (RA). Method...

Full description

Bibliographic Details
Main Authors: Ridhima Vij, Kevin A. Stebbings, Hosu Kim, Hyeonggeun Park, Donna Chang
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Stem Cell Research & Therapy
Subjects:
Adipose-derived mesenchymal stem cell
Autologous
Clinical trial
Rheumatoid arthritis
Intravenous
Efficacy
Online Access:https://doi.org/10.1186/s13287-022-02763-w

Internet

https://doi.org/10.1186/s13287-022-02763-w

Similar Items